Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘CD138’

ASH20 Preview 2 on Antibodies and ADCs

Upregulation of ligands and receptors provides handy targets for antibodies and ADCs

Anyone who has been casually following oncology R&D over the last five years might be forgiven for thinking the gold rush and panning for nuggets in IO might have overtaken company interest in targeted therapies, whether they be small molecules, antibodies, or ADCs.

As hematologic malignancies evolve, proteins are upregulated on the surface of the cancer cells, providing a variety of novel targets to aim at therapeutically.

For those in the know, however, the quality of research in the targeted niche remains at a very high level with some serious research going on behind the scenes in terms of novel targets, focused clinical developments (i.e. not treating a targeted agent in an untargeted fashion), and even enhanced design of next generation molecules coming to the fore…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH20 virtual conference — including our second meeting Preview — subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASH 2013 Multiple Myeloma Preview

This year at the American Society of Hematology (ASH) there are over 800 abstracts on multiple myeloma alone. Obviously, one can’t possible do them all justice, but there are a number of important ones that are well worth highlighting, especially given the raft of new products in development, as well as some solid data from existing approved products.

Myeloma has long been dominated by proteasome inhibitors and immunomodulatory (IMiD) agents in combination with prednisone, dexamethasone, melphalan or as a triplet such as RVd, VMP etc. In Europe, melphalan still dominates as part of the base therapy, while in the US, dexamethasone (dex or simply d) is preferred partner since the tolerability is much improved along with a lower risk for secondary primary malignancies (SPMs).

In this detailed preview, the following companies and products are covered:

Companies: Millennium, Celgene, J&J, Amgen, Novartis, GSK, Array, Actelion, Biotest, KaloBio, Curis, Verastem, Karyopharm, Aeterna Zentaris.
Products: Ixazomib, lenalidomide, pomalidomide, carfilzomib, panobinostat, daratumumab, ibrutinib, CC-292, afuresertib, GSK2857916, ARRY-520, ACY-1215, indatuximab ravtansine, CUDC-907, VS-5584, selinexor, LCL161, BYL917, perifosine.

I also discuss some controversial topics such as lack of overall survival in the Revlimid trials and the risk of cardiovascular adverse events with Kyprolis. There are also an exciting raft of new compounds with new targets in various stages of development.

Obviously there will be more to come at the meeting, but for now, there’s plenty to discuss and review ahead of time.

To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below… 

This content is restricted to subscribers

error: Content is protected !!